Question · Q2 2025
Imogen Mansfield of Cantor Fitzgerald inquired about any updates to the safety profile of ometipivat (Pyrokine), specifically regarding liver toxicity, and asked for more details on the expected approval timeline in the GCC region.
Answer
Chief Medical Officer Dr. Sarah Gheuens confirmed there were no new updates to the drug's safety profile. CEO Brian Goff stated that regulatory filings were submitted simultaneously in four regions and discussions are active, but did not provide a specific timeline for the GCC approval.
Ask follow-up questions
Fintool can predict
AGIO's earnings beat/miss a week before the call